Challenges in clinical trials for high-risk but curable prostate cancer

被引：1
|
作者：
Dorff, Tanya Barauskas [1 ,3 ]
Bryce, Alan H. [2 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] City Hope Phoenix, Dept Med Oncol & Therapeut Res, Phoenix, AZ USA
[3] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 E Duarte Rd, PAV2250, Duarte, CA 91010 USA
来源：
CANCER | 2024年 / 130卷 / 09期
关键词：
androgen-deprivation therapy; clinical trial recruitment and retention; patient advocate; prostate cancer; prostatectomy;
D O I：
10.1002/cncr.35245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical trials studying neoadjuvant and adjuvant therapy around prostatectomy for patients with high-risk prostate cancer have faced multiple challenges. Patients who have a very good response to neoadjuvant therapy may not wish to continue to adjuvant treatment, and prostate-specific antigen-based end points are difficult to interpret because of variations in testosterone recovery.
引用
收藏
页码：1575 / 1576
页数：2
相关论文
共 50 条
  • [1] Radical prostatectomy in high-risk prostate cancer
    Ischia, Joseph
    Gleave, Martin
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (03) : 290 - 300
  • [2] High-risk clinically localised prostate cancer
    Rozet, F.
    Cornu, J-N.
    Cussenot, O.
    Fromont, G.
    Hennequin, C.
    BULLETIN DU CANCER, 2010, 97 (12) : 1517 - 1536
  • [3] Radical Prostatectomy for High-risk Prostate Cancer
    Karnes, R. Jeffrey
    Hatano, Tadashi
    Blute, Michael L.
    Myers, Robert P.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 3 - 9
  • [4] Surgical treatment of high-risk prostate cancer
    Soares, R.
    Eden, C. G.
    MINERVA UROLOGICA E NEFROLOGICA, 2015, 67 (01) : 33 - 46
  • [5] Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Matsumoto, Hiroaki
    Nasu, Takahito
    Yamamoto, Mitsutaka
    Kamiryo, Yoriaki
    Baba, Yoshikazu
    Suga, Akinobu
    Tei, Yasuhide
    Yoshihiro, Satoru
    Aoki, Akihiko
    Shimabukuro, Tomoyuki
    Joko, Keiji
    Sakano, Shigeru
    Takai, Kimio
    Yamaguchi, Shiro
    Akao, Jumpei
    Kitahara, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) : 757 - 764
  • [6] Approach to the Patient with High-Risk Prostate Cancer
    Mossanen, Matthew
    Krasnow, Ross E.
    Nguyen, Paul L.
    Trinh, Quoc D.
    Preston, Mark
    Kibel, Adam S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 635 - +
  • [7] Management of High-Risk Localised Prostate Cancer
    Ozen, Haluk
    Yazici, Sertac
    Inci, Kubilay
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (05) : 439 - 447
  • [8] Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
    Philipson, Rebecca G.
    Romero, Tahmineh
    Wong, Jessica K.
    Stish, Bradley J.
    Dess, Robert T.
    Spratt, Daniel E.
    Pilar, Avinash
    Reddy, Chandana
    Wedde, Trude B.
    Lilleby, Wolfgang A.
    Fiano, Ryan
    Merrick, Gregory S.
    Stock, Richard G.
    Demanes, D. Jeffrey
    Moran, Brian J.
    Braccioforte, Michelle
    Tran, Phuoc T.
    Martin, Santiago
    Martinez-Monge, Rafael
    Krauss, Daniel J.
    Abu-Isa, Eyad I.
    Valle, Luca
    Chong, Natalie
    Pisansky, Thomas M.
    Choo, C. Richard
    Song, Daniel Y.
    Greco, Stephen
    Deville, Curtiland
    McNutt, Todd
    DeWeese, Theodore L.
    Ross, Ashley E.
    Ciezki, Jay P.
    Tilki, Derya
    Karnes, R. Jeffrey
    Klein, Eric A.
    Tosoian, Jeffrey J.
    Boutros, Paul C.
    Nickols, Nicholas G.
    Bhat, Prashant
    Shabsovich, David
    Juarez, Jesus E.
    Kupelian, Patrick A.
    Rettig, Matthew B.
    Berlin, Alejandro
    Tward, Jonathan D.
    Davis, Brian J.
    Reiter, Robert E.
    Steinberg, Michael L.
    Elashoff, David
    Horwitz, Eric M.
    EUROPEAN UROLOGY, 2021, 80 (02) : 142 - 146
  • [9] Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
    Kazuhiro Nagao
    Hideyasu Matsuyama
    Hiroaki Matsumoto
    Takahito Nasu
    Mitsutaka Yamamoto
    Yoriaki Kamiryo
    Yoshikazu Baba
    Akinobu Suga
    Yasuhide Tei
    Satoru Yoshihiro
    Akihiko Aoki
    Tomoyuki Shimabukuro
    Keiji Joko
    Shigeru Sakano
    Kimio Takai
    Shiro Yamaguchi
    Jumpei Akao
    Seiji Kitahara
    International Journal of Clinical Oncology, 2018, 23 : 757 - 764
  • [10] High-risk prostate cancer: treat the prostate
    Cooperberg, Matthew R.
    LANCET, 2011, 378 (9809) : 2056 - 2057
12345